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Objective: The objective of this study was to compare systemic exposure to tropicamide/
phenylephrine following intracameral or topical administration before cataract surgery.
Patients and methods: Mydriatics exposure was calculated in patients randomized to 
intracameral fixed combination of mydriatics and anesthetic ([ICMA]: tropicamide 0.02%, 
phenylephrine 0.31%, and lidocaine 1%, N=271) or mydriatic eye drops ([EDs]: tropicamide 
0.5% and phenylephrine 10%, N=283). Additional doses were permitted if required. Mydriatic 
plasma levels were determined by mass spectrometric HPLC in 15 patients per group before 
and after administration.
Results: Most ICMA patients (73.6%) received a single dose (200 µL) representing an exposure 
to tropicamide of 0.04 mg and phenylephrine of 0.62 mg. None of these patients received addi-
tional mydriatics. In the control group (three administrations), the exposure was 0.45 (11.3-fold 
higher than ICMA) and 10.2 (16.5-fold higher) mg. When additional ED was used in this group 
(9.2% of patients), it was 37.5-fold higher for tropicamide (10 drops, 1.5 mg) and 54.8-fold 
higher for phenylephrine (10 drops, 34 mg) than the recommended ICMA dose. Tropicamide 
plasma levels were not detectable at any time point in ICMA patients while it was detectable in 
all ED patients at 12 and 30 minutes. Phenylephrine was detectable in 14.3% of ICMA patients 
compared to all ED patients at least at one time point. More ED patients experienced a mean-
ingful increase in blood pressure and/or heart rate (11.2% vs 6.0% of ICMA patients; P=0.03).
Conclusion: Systemic exposure to tropicamide/phenylephrine was lower and cardiovascular 
(CV) effects were less frequent with ICMA. This could be of particular significance in patients 
at CV risk.
Keywords: cataract surgery, intracameral mydriasis, topical mydriasis, systemic influence, 
cardiovascular safety
Introduction
Cataract surgery is the second most commonly undertaken surgical procedure after 
intravitreal injections.1 Cataract is associated with old age and, as the population ages, 
the demand for cataract surgery is increasing and will likely continue to increase. 
Additionally, elderlies are at an increased risk of developing multiple pathologies and 
are consequently polymedicated. Moreover, diagnosis and screening for cataract are 
improving, putting further pressure on health care resources that may not be keeping 
pace with the demand.1,2
A stable mydriasis is required for successful cataract surgery and lens implantation. 
The combination of tropicamide and phenylephrine eye drops (EDs) is the current 
gold standard for most surgeons worldwide, but the usual regimen requires multiple 
instillations that could possibly expose to overdose associated with increased risk of 
cardiovascular (CV) events. Moreover, a particular side effect of local overdose is the 
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ocular surface toxicity leading to toxic keratopathy that may 
interfere with the quality of visualization during surgery.3 An 
alternative could be the use of a mydriatic insert that ensures 
a better control of the delivered dose of mydriatics,4,5 but 
the potential disadvantage is the longer time required for 
obtaining the optimal mydriasis, and the risk of local toxicity 
remains. The drawback of all these approaches is the need to 
start the administration at least 30 minutes before the surgery, 
and the prolonged supervision of patients by nurses to first 
instill the ED and monitor the mydriasis. Today, mydriatic 
EDs are most frequently initiated by a nurse in the ambula-
tory surgical center (82% of cases). For the 14% of patients 
who administer their mydriatic EDs at home,6 the medical 
supervision of mydriatic ED application is limited and it 
also increases the risk of CV side effects (for the remaining 
4%, dilation is performed in the operating room). Changes 
in surgical scheduling are also common and may call for 
multiple applications of mydriatic preparations to ensure the 
pupil is appropriately dilated at the time of the surgery. Thus, 
for a variety of reasons cataract patients may be exposed to 
higher level than anticipated levels of mydriatics with pos-
sible topical and systemic implications.
In order to improve the process of mydriasis in routine 
cataract surgery, the intracameral application of mydriatic 
drugs has been explored and found to be safe and effective.7–9 
Based on these pioneering studies, an intracameral formu-
lation to be injected at the start of the surgery has been 
developed, comprising a mix of two synergistic mydriatics 
(tropicamide, a lipophilic anticholinergic agent and phen-
ylephrine, a sympathomimetic agent) in addition to an 
anesthetic (lidocaine) to improve preoperative intraocular 
anesthesia.
A particular benefit of intracameral mydriatics/anesthetic 
is the excellent bioavailability directly in the target tissues 
and the putative lower systemic absorption compared to ED 
formulations. The synergistic effect of the two mydriatic 
components also permits lower doses of each to be used, 
further limiting the local toxicity of these drugs.10
A pivotal Phase III study has been completed comparing 
a standardized (quality-controlled) intracameral fixed com-
bination of mydriatics and anesthetic (ICMA) with standard 
topical mydriatics regimen that confirmed excellent efficacy 
in terms of quickly initiating and maintaining mydriasis and 
a good safety profile for ICMA.11 Patients who received 
ICMA were significantly more comfortable during surgery 
and spent less time overall in the preoperative and surgical 
room than those who received standard mydriatic EDs. 
Moreover, surgeons found the insertion of the intraocular lens 
technically less demanding with ICMA compared to EDs.11
In the present report, we provide additional information 
on the systemic exposure to mydriatic components with the 
ICMA formulation in comparison to the standard topical 
administration. This study is a supplementary analysis of 
data collected during the Phase III clinical study on received 
doses and plasma pharmacokinetics that were not previously 
reported.11
Patients and methods
Study design
Data from the Phase III European Union approval study of 
ICMA (Mydrane®; Laboratoires Théa, Clermont-Ferrand, 
France) were used to compare patient systemic exposure to 
mydriatic agents. Immediately after the arrival in the surgery 
unit, patients were randomized to receive either ICMA at the 
beginning of cataract surgery or standard topical mydriatics.11 
Mydrane® is a proprietary injectable salt- and pH-balanced 
solution of two mydriatics (tropicamide 0.02% and phenyl-
ephrine 0.31%) and one anesthetic agent (lidocaine 1%) for 
intracameral delivery at the beginning of cataract surgery. The 
standard topical mydriatic regimen consisted of tropicamide 
0.5% (Mydriaticum® 0.5%; Laboratoires Théa) and phenyl-
ephrine 10% (Neosynephrine® 10% Faure; Les Laboratoires 
Europhta, Gabian, Monaco). The parameters reported in this 
study formed part of the secondary objectives of that study.
ethics
The study was performed in compliance with the ethical 
principles having their origins in the Declaration of Helsinki 
(2004) regarding biomedical research on human patients. The 
study was conducted in compliance with applicable regula-
tory requirements and in accordance with Good Clinical 
Practice using the guidance documents and practices of the 
International Conference on Harmonization and the European 
directive 2001/20/CE.
Independent ethics committee approval was obtained for 
each participating center prior to patient recruitment in each 
center (Supplementary material). Written and oral informa-
tion was provided to each patient by the local investigator, 
and signed written consent was obtained before the patient 
was enrolled.
Study population
Patients
The study population comprised male or female cataract 
patients aged 40–88 years undergoing scheduled unilateral 
cataract surgery under topical anesthesia with clear corneal 
self-sealing incisions by phacoemulsification. Patients were 
only included if they demonstrated good mydriasis ($7 mm) 
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with topical mydriatics at the preoperative (selection) visit. 
Main noninclusion criteria included: a history of intraocular 
surgery or combined procedures, iatrogenic, traumatic, or 
congenital cataract, corneal, epithelial, stromal, or endo-
thelial residual, progressive corneal disease, history of 
ocular trauma, infection or inflammation within the previous 
3 months, and pseudoexfoliation and exfoliation syndromes.
Setting
Subjects were recruited from outpatient cataract surgery 
clinics in nine countries. Of 609 patients screened, 591 were 
randomized, 555 underwent the surgery, and 554 provided 
data for safety. Thirty patients from two centers ([Centre Hos-
pitalier Régional Universitaire; CHRU Bretonneau of Tours 
and Centre Hospitalier Universitaire Dupuytren of Limoges, 
France) were selected for analysis of plasma tropicamide and 
phenylephrine levels.
Study interventions
To perform the mandatory preoperative step of antiseptics 
(5% povidone-iodine, Betadine®, in the ophthalmic area), all 
patients received topical anesthesia with one or two drops of 
tetracaine 1% instilled into the eye 5 minutes before surgery 
and a second identical instillation 1 minute before surgery.
Patients randomized to ICMA received the currently 
approved dose of ICMA, ie, a single injection of 200 µL 
administrated intracamerally through the side port or principal 
port at the beginning of the surgery. At this stage of the drug 
development, a supplementary 100-µL injection could be 
performed at the operating surgeon’s discretion.
Reference therapy comprised one drop of tropicamide 
0.5% and one drop of phenylephrine 10%, instilled into the 
eye 30, 20, and 10 minutes prior. Further mydriatic EDs 
could be given at the operating surgeon’s discretion, in case 
of insufficient mydriasis.
Study outcomes
Determination of total exposure
Total exposure to their respective treatment was recorded in 
terms of intracameral dose of ICMA or number of drops of 
reference therapy in the overall population. For ICMA, the 
received dose was calculated based on the recorded volume 
injected in the anterior chamber and the concentration of each 
mydriatic in the ICMA solution. The patient’s exposure to 
the reference therapy was deduced from the amount of phen-
ylephrine and tropicamide delivered with each instilled drop 
(0.15 and 3.4 mg, respectively, according to their respective 
summaries of product characteristics).3 To remain in a con-
servative hypothesis (sensibility analysis), it was assumed 
that only one drop was instilled per administration.
Sample collection and analysis (subgroup of patients)
Plasma levels of tropicamide and phenylephrine were 
measured in 30 patients (15 patients in each group) from two 
centers having appropriate technical and logistic ability. Blood 
samples (6 mL) were collected in heparinized tubes before 
and 2, 12, and 30 minutes after injection of ICMA or instilla-
tion of reference treatment. Blood samples were immediately 
centrifuged at 1,500× g for 10 minutes at 5°C. Plasma was 
harvested and transferred into polypropylene tubes for storage 
at −20°C. The frozen samples were shipped to SGS Cephac 
Europe SAS (Saint-Benoît, France) for bioanalysis. Plasma 
concentrations of tropicamide and phenylephrine were deter-
mined by HPLC with mass spectrometric detection (threshold 
of detection was 0.1 ng/mL). For both mydriatics, means of 
plasma levels were analyzed as well as the rate of patients 
presenting with plasma level above the limit of detection.
Vital signs
SBP (in mmHg), DBP (in mmHg), and heart rate (HR, radial 
pulses in beats/minute, bpm) were measured at the selection 
visit (60–70 days prior to surgery), then on the day of surgery 
(Day 0; before, during [5 minutes after the first incision], 
and at the end of surgery) and after 1, 8, and 28 days in the 
overall population. Two measurements were performed (with 
a resting time of 5 minutes between the two measurements), 
except during and at the end of the surgical procedure (for 
practical reasons). Means of the CV parameters were ana-
lyzed, and a post hoc analysis was performed to compare 
the rate of patients presenting with either at least one DBP 
value .100 mmHg, one SBP value .200 mmHg, or one HR 
value .120 bpm between groups.
Results
A total of 271 patients were exposed to ICMA and 283 
patients to the reference treatment (hereinafter referred to as 
the safety set). Baseline characteristics of the overall study 
population were previously reported.11 For the subgroup 
of 30 patients who underwent blood sampling, mean age 
was 71.3±8.8 years (range: 51.3–85.5 years), with a large 
majority .65 years (80.0%) and more females than males 
(66.7% vs 33.3%, respectively).
Total exposure
In the ICMA group, all patients received 200 µL of ICMA 
in the operated eye, and the patient’s total exposure (without 
additional injection) was calculated to be 0.04 mg tropi-
camide and 0.62 mg phenylephrine. In addition, 72 (26.6%) 
patients received an additional injection of 100 µL of ICMA, 
and a single patient received a third 100-µL injection. Patients 
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receiving one additional 100 µL of ICMA received maximum 
doses of 0.06 mg tropicamide and 0.93 mg phenylephrine.
In the reference group, the regimen was one drop of 0.5% 
tropicamide plus one drop of 10% phenylephrine thrice in the 
eye to be operated. These EDs were administered alternately 
10 minutes apart. The patients’ exposure to tropicamide and 
phenylephrine was, respectively, 0.45 and 10.2 mg. This 
represents 11.3 and 16.5 times more drug exposure compared 
to ICMA at a dose of 200 µL (Table 1). In the reference treat-
ment group, 23 (8.1%) patients received additional drops of 
tropicamide and 22 (7.8%) patients received extra drops of 
phenylephrine. In these patients, the total dose varied between 
4 and 10 drops (0.6–1.5 mg tropicamide and 13.7–34.0 mg 
phenylephrine). In case of 10 drops, this represents a dose 
ratio of 37.5 and 54.8 as compared to ICMA for tropicamide 
and phenylephrine, respectively.
Plasma levels
All 30 patients with blood sampling received the standard 
regimen of mydriatics (200 µL of ICMA or three drops each 
of tropicamide and phenylephrine), with the exception of 
one patient in the ICMA group who received an additional 
100-µL injection.
Tropicamide plasma levels were below the limit of 
detection at all time points (2, 12, and 30 minutes) following 
ICMA injection in all patients (Figure 1). In patients receiv-
ing the reference regimen tropicamide was detectable in the 
plasma (73.3%) at 2 minutes, and in all patients at 12 and 
30 minutes. The maximum plasma tropicamide concentra-
tion was 3.16 ng/mL at 30 minutes in the reference group.
Phenylephrine was only detectable in the plasma of two 
patients in the ICMA group (Figure 2); the maximum plasma 
phenylephrine concentration observed in these two patients 
were 0.140 and 0.587 ng/mL. In contrast, phenylephrine was 
detectable in plasma in all patients in the reference treatment 
group at least at one time point (depending on the patient, 
the maximum concentration ranged between 0.109 and 
1.42 ng/mL). Maximal plasma phenylephrine concentration 
exceeded 0.59 ng/mL in 38.5% of patients.
Vital signs
When mean blood pressure or HR was considered, no 
changes of note were detected among the 271 patients of the 
ICMA group and the 283 patients treated with reference treat-
ment (Table 2). However, when CV events were analyzed 
based on the rate of patients presenting with either at least 
Table 1 Total exposure to mydriatics in patients receiving the standard topical regimen
Recommended dose (3 drops) Maximal dose (4–10 drops)
N Dose Ref/ICMAa 
dose ratio
N Dose (mg) Ref/ICMAa 
dose ratio
Tropicamide 260 (91.9%) 0.45 mg 11.3 23 (8.1%) 0.60–1.5 15.0–37.5
Phenylephrine 261 (92.2) 10.2 mg 16.5 22 (7.8) 13.6–34 21.9–54.8
Note: aFor the recommended dose of iCMa (one injection of 200 µl), the total exposure is 0.04 mg for tropicamide and 0.62 mg for phenylephrine.
Abbreviations: ICMA, intracameral fixed combination of mydriatics and anesthetic; Ref, reference.
Figure 1 Plasma tropicamide levels during surgery for iCMa and reference treatments.
Notes: Columns show the proportion of patients with tropicamide levels above the limit of detection and the lines show tropicamide levels (mean ± SD). Blood samples 
were collected before (T0) and 2 (T1), 12 (T2), and 30 (T3) minutes after injection of iCMa or instillation of reference treatment. Tropicamide was not detected in the 
plasma of any iCMa-treated patient.
Abbreviation: ICMA, intracameral fixed combination of mydriatics and anesthetic.
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one DBP value .100 mmHg, one SBP value .200 mmHg, 
or one HR value .120 bpm, instances of hypertension 
or tachycardia events were statistically more common in 
patients who received reference treatment (11.2%) than in 
the ICMA group (6.0%; P-value =0.033).
Discussion
While cataract surgery cannot proceed without adequate 
mydriasis, mydriatic drugs have the potential to cause CV 
adverse events. This is a particular concern in the generally 
older patient population undergoing cataract surgery. 
In a busy presurgical room with a number of patients being 
treated with EDs, the possibility for overdose errors is ever 
present. Surgery may be delayed and extra drops may be 
required to provide adequate mydriasis at the time of the 
rescheduled surgery. Moreover, some patients who com-
mence mydriasis at home before coming to the ophthalmic 
surgical unit may either inadvertently or forgetfully admin-
ister more than one drop, or may be inadequately dilated at 
the commencement of surgery. Lastly, imperfect instillation 
Figure 2 Plasma phenylephrine levels during surgery for iCMa and reference treatments.
Notes: Columns show the proportion of patients with phenylephrine levels above the limit of detection and the lines show phenylephrine levels (mean ± SD). Blood 
samples were collected before (T0) and 2 (T1), 12 (T2), and 30 (T3) minutes after injection of iCMa or instillation of reference treatment. The phenylephrine analyses for 
three samples (one from the iCMa group and two from the reference treatment group) were rejected because they were analyzed after the validated stability period for 
phenylephrine.
Abbreviation: ICMA, intracameral fixed combination of mydriatics and anesthetic.
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Table 2 Blood pressure and Hr before, during, and after mydriatic treatment
Day 60/70 Before surgery During surgerya End of surgery Day 1 Day 8
Mean SBP (mmHg)
iCMa
reference treatment
137.3
138.1
143.9
142.6
147.9
148.1
146.2
146.8
136.1
135.1
135.5
135.6
Min/max SBP (mmHg)
iCMa
reference treatment
101/280
100/220
90/218
96/197
75/208
100/218
96/210
96/210
102
98
100/203
95/200
Mean DBP (mmHg)
iCMa
reference treatment
78.0
78.6
78.3
77.9
79.0
79.5
78.0
79.0
76.6
77.6
77.3
77.2
Min/max DBP (mmHg)
iCMa
reference treatment
52/120
50/110
40/110
44/110
38/115
44/110
42/119
45/113
52/105
50/150
51/119
50/118
Mean Hr (beats min−1)
iCMa
reference treatment
70.5
70.5
71.5
71.3
72.2
71.7
70.6
71.3
69.6
70.1
70.4
70.8
Min/max Hr (beats min−1)
iCMa
reference treatment
37/100
44/142
43/125
44/145
44/126
45/141
44/125
46/154
42/109
41/137
40/110
47/142
Note: aFive minutes after the first incision.
Abbreviations: HR, heart rate; ICMA, intracameral fixed combination of mydriatics and anesthetic.
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technique may result in patients receiving more than one 
drop per administration.
The present shows that the total exposure to mydriatic 
agents is different between the reference topical regimen and 
the intracameral administration, resulting in differences in 
plasma levels. Even in the controlled environment of this 
clinical trial, ~9% of ED patients received additional drops 
of the reference ED formulation, with some receiving as 
many as 10 drops. None of these patients were included in 
the subset analyzed for plasma phenylephrine levels, but it 
is reasonable to assume that their exposure to phenylephrine 
would be higher than those who received the recommended 
dose. In daily practice, the recommendation for one drop per 
instillation is not universally respected during the presurgical 
phase of the patient’s care, especially when the patient self-
instill the EDs.
The plasma levels were not excessive in the patients 
included in the relatively small subset of 30 patients analyzed 
for plasma mydriatic levels, and CV events were absent in 
the controlled context of this clinical study. In the less rigor-
ously controlled environment of everyday clinical practice, 
however, extra drops are frequently used (indeed were used 
in this study). In this Phase III clinical trial, levels measured 
in the plasma of patients who received ICMA were much 
lower than those in patients who received the reference treat-
ment. As reported in previous clinical studies on intracameral 
mydriatics, there were no systemic adverse effects reported 
in this study.12,13 Bearing in mind that patients undergoing 
cataract surgery are generally elderly and frequently have 
preexisting CV pathologies, any additional sympathetic 
activation consequent on the systemic passage of phenyleph-
rine from mydriatic medication is to be avoided. The patient 
population in the present study may have been at lower risk of 
CV adverse effects than cataract surgery patients in general 
since patients with uncontrolled diabetes, excessive anxiety, 
uncontrolled hypertension, and other CV diseases were not 
included in this study.
A number of other studies have reported CV adverse 
effects with both 2.5% and 10% phenylephrine EDs.14 
Our study results on HR and blood pressure measurements 
suggested that more patients might present with one 
meaningful CV event defined as one DBP value .100 mmHg, 
one SBP value .200 mmHg, or one HR value .120 bpm in 
the group receiving mydriatic EDs than in the ICMA group. 
Similar to our clinical trial, a comparative study of different 
mydriatic approaches in cataract surgery showed that the 
intracameral route is likely the safest from a CV perspective, 
presumably a reflection of the low doses of direct and indirect 
sympathomimetics used.15 However, in our study, no major 
differences were detected when the mean CV parameters 
were considered. This might be due to the fact that cataract 
surgery is a stressful experience for patients, especially in the 
context of a clinical trial. Therefore, difference in the mean 
CV parameters might have been diluted by patients experi-
encing an increase in their vital signs due to this stressful 
environment. This phenomenon was notable in the ICMA 
group where many patients already experienced an increase 
in blood pressure before receiving the study product. This 
stressful environment is well recognized in the literature since 
around half of patients report anxiety, even panic attacks, 
associated with the sensations of surgery and such reactions 
are likely to induce a sympathetic response with elevation 
of HR and blood pressure.16–18
Intracameral mydriasis provides auxiliary benefits; 
patients spend less time in the waiting room7 (potentially 
reducing stress and anxiety) and the risk of inadequate 
mydriasis jeopardizing operating room schedules is dimin-
ished. On the other hand, topical mydriatic EDs need to 
be instilled 30 minutes to 2 hours prior to cataract surgery 
(either in the waiting room or at home) in order to ensure 
adequate mydriasis at the time of capsulorhexis and further 
steps of phacoemulsification and lens implantation. Obvi-
ously, ED administration at home is entirely unsupervised; 
moreover, in a busy surgical department the degree of 
supervision of each patient is necessarily limited and the 
potential for medication errors and overdose exists.19,20 In 
addition, ocular surface toxicity may occur after multiple 
dosages of EDs including tropicamide, phenylephrine, and 
topical anesthetics (eg, oxybuprocaine or tetracaine).3,21 The 
toxically induced superficial punctate keratopathy may lead 
to suboptimal visualization during surgery (this is being 
prospectively evaluated in another ongoing study). By con-
trast, injection in the anterior chamber, directly to the target 
tissue, permits the induction of mydriasis in the operating 
room by the surgeon so the patient is under supervision 
throughout the entire procedure, and no side effects on the 
corneal epithelium can occur.
Two recent studies have attested to the benefits of intra-
cameral mydriasis in terms of pre- and intraoperative opera-
tions and patient experience.22,23
Conclusion
In conclusion, ICMA result has lower systemic ocular sur-
face exposure to phenylephrine and tropicamide than the 
reference topical treatment. It permits the correct dose of 
the appropriate agents to be administered consistently at a 
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convenient time (at the start of surgery), in a safe and moni-
tored environment (the operating room) at an appropriate 
site (anterior chamber) with less CV side effects compared 
to the usual dilation procedure.
Data sharing
Since the data were collected from a clinical trial, these are 
not intended to be shared by the authors, and no other study-
related documents will be made available.
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